Clinical trial · Interventional
Identification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients With Ovarian Cancer Who Are Refractory to Platinum-based Therapy From Patients Defined as Long-term Responders to Platinum-based Therapy
Identification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients With Ovarian Cancer Who Are Refractory to Platinum-based Therapy From Patients Defined as Long-term Responders to Platinum-based Therapy.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
After having constituted the ORTRAI cohort using the CONSORE database at the Jean PERRIN Center, the objective is to characterize the patients both clinically and biologically, histologically and genomically. The clinical and biological characterizations will allow us to confirm that our cohort is comparable with data from the literature. The complement of immunohistochemical and molecular analyses will provide more details on the differences between long-term patients responding to treatment and refractory patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| molecular analysis | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- long-term responders
- description
- molecular analysis on histological blocks
- interventionNames
- Genetic: molecular analysis
Primary outcomes (1)
- measure
- Molecular anomalies retained after biological interpretation and allowing the differentiation of refractory patients from long-term responder patients.
- timeFrame
- Through study completion, an average of 1 year
- description
- Refractory patients are defined as any patient progressing through the first therapeutic line of platinum-based chemotherapy. Long responders are defined as any patient who has not progressed within 5 years of the end of platinum salt treatment.
Secondary outcomes (4)
- measure
- Phenotypic criteria differences between refactory patients and long responder patients
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Major patient, treated at the Jean Perrin Center, suffering from ovarian cancer at any stage and treated with platinum-based chemotherapy in the first line of treatment. * Corresponding to one of the two groups below: * Refractory group: patients progressing in the first therapeutic line of platinum-based chemotherapy. * Group of long-term responders: patients who have not progressed 5 years after the end of first-line platinum salt treatment * Affiliation to a social security scheme * Patient who signed the genetic consent form Exclusion Criteria: * Minor patient * Pregnant patient * Patient under guardianship or conservatorship * Patients who object to the collection of their medical/paramedical data * Patient for whom the center does not have biological material for genomic analysis (FFPE block) * Patient under administrative, judicial decision or AME (State Medical Aid)
References
Publications (0)
Data not yet available